Compare KGS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | BLCO |
|---|---|---|
| Founded | 2011 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Ophthalmic Goods |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.1B |
| IPO Year | 2023 | 2022 |
| Metric | KGS | BLCO |
|---|---|---|
| Price | $51.09 | $15.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 15 |
| Target Price | ★ $81.40 | $19.39 |
| AVG Volume (30 Days) | ★ 1.7M | 411.0K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $16.21 | $7.68 |
| Revenue Next Year | $15.12 | $5.95 |
| P/E Ratio | $69.95 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $32.55 | $14.44 |
| 52 Week High | $77.68 | $18.92 |
| Indicator | KGS | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 35.69 | 32.66 |
| Support Level | $51.15 | $15.68 |
| Resistance Level | $52.70 | $16.41 |
| Average True Range (ATR) | 2.00 | 0.43 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 25.76 | 20.69 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.